Incorporated in 1981, Emcure Pharmaceuticals Ltd manufactures and markets pharmaceutical products globally. EPL develops, manufactures, and markets a broad range of pharmaceutical and biopharmaceutical products across a wide range of dosage forms, including oral solids, oral liquids, injectables (including liposomal and lyophilized injectables), biotherapeutics, and complex APIs (including chiral molecules, iron molecules, and cytotoxic products).
Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing, and globally marketing a broad range of pharmaceutical products. It has a presence in all major therapeutic areas including Gynaecology, cardiology, blood-related, oncology, respiratory, CNS & HIV etc. Company has 350+ brands, with a wide network across 70+ countries.
Emcure Pharmaceuticals has a Market Cap of ₹23,732 Crore as of June 2025. Today's market capitalization of Emcure Pharmaceuticals Ltd is ₹24,984.78 Crore. The company's stock performance shows Emcure Pharmaceuticals Ltd's 52-week high is ₹1580 and 52-week low is ₹889.
Emcure Pharmaceuticals posted a 63% year-on-year (Y-o-Y) growth in its consolidated net profit at ₹197.2 Crore for the March quarter of financial year 2024–25 (Q4 FY25), up from ₹121 Crore in the same period last year. The company's revenue from operations rose to ₹2,116.2 Crore, a 19.5% increase from ₹1,771.3 Crore in Q4 FY24.
Key Q4 FY25 Financial Highlights:
- Revenue: ₹2,116.25 Crore (March 2025)
- Net Profit: ₹197.24 Crore (March 2025)
- Net profit surged 64.07% to ₹188.96 Crore, while EBITDA rose 25.92% to ₹406.86 Crore.
- EPS increased to ₹9.97 from ₹6.36.
Emcure discloses FY25 KPIs: EBITDA ₹15,313 million, PAT ₹7,075 million, RoCE 22.04%, revenue split India 46.34%, outside India 53.65%. Revenue: ₹7,896 Crore. Profit: ₹707 Crore.
The company's consolidated net profit surged 35.5% to ₹153.72 Crore in Q3 FY25 as against ₹113.45 Crore posted in Q3 FY24. Revenue from operations jumped 17.7% YoY to ₹1,962.63 Crore in the quarter ended December 31, 2024.
The Company has a portfolio of six commercialized and in-house manufactured biologics and biologics brands, Elaxim, Tenectase and Hamsyl, each launched into domestic market for the Financial Year 2021. The Company launched biosimilar for Tenecteplase, commonly used for acute myocardial infraction, and the biosimilar for Pegylated-asparaginase, commonly used for treating patients with leukemia.
Through Subsidiary, Zuventus Healthcare Limited, a manufacturing facility was established in Bengaluru in year 2017 and finally, the Company received licence to work a factory at Sanand, Gujarat in 2018. The company maintains international quality standards and The company received the Establishment Inspection Report (EIR) from the USFDA following an inspection conducted between February 19, 2025, and February 25, 2025. According to an exchange filing dated February 26, 2025, the inspection concluded with the issuance of two observations in Form 483.
Emcure Pharmaceuticals demonstrated robust performance in Q4 FY25, achieving a 19.5% revenue growth fueled by strong domestic and international sales, while maintaining stable margins at 18.6%. The company is strategically expanding its product pipeline, particularly in dermatology and women's health, and is optimistic about future growth, projecting a 13% to 14% increase in FY26.
Emcure Pharmaceuticals announced plans to acquire the remaining 20.42% stake in Zuventus Healthcare for ₹724.9 Crore, aiming for full ownership and financial consolidation. The transaction is expected to close in the September quarter of FY26, enhancing strategic alignment and long-term value creation.
Promoter Holding: 77.9%. Promoter holding in Emcure Pharmaceuticals Ltd has gone down to 77.94% as of December 2024 from 78.08% as of July 2024.
Stock P/E 34.5 · Book Value ₹235 · Dividend Yield 0.00 % ROCE 20.8 % ROE 18.6 %. An annual revenue growth of 11% is good, Pre-tax margin of 11% is healthy, ROE of 16% is good. The company has a reasonable debt to equity of 26%, which signals a healthy balance sheet.
The board proposed a final dividend of ₹3 per share, reflecting strong financial performance for FY25, demonstrating the company's commitment to returning value to shareholders.
